Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma
NCT05169658Phase 2Completed
- Sponsor
- University of Washington
- Start
- Mar 2022
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab in B-cell non-Hodgkin lymphoma, sponsored by University of Washington. Started Mar 2022; status: completed.
02
Drugs
mosunetuzumab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05169658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169658.